[Federal Register Volume 62, Number 114 (Friday, June 13, 1997)]
[Notices]
[Pages 32340-32345]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-15510]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention
[Announcement 750]


HIV and STD Intervention Research for Young Men in Prison

Introduction

    The Centers for Disease Control and Prevention (CDC) announces the 
availability of fiscal year (FY) 1997 funds for a cooperative agreement 
program to stimulate the development of innovative science-based models 
that assist local communities in the prevention of HIV/STD infection 
and transmission among young men in prison who are ready to return to 
their communities.
    CDC is committed to achieving the health promotion and disease 
prevention objectives of ``Healthy People 2000,'' a national activity 
to reduce morbidity and mortality and improve the quality of life. This 
announcement is related to the priority area Human Immunodeficiency 
Virus (HIV) Infection. (For ordering a copy of ``Healthy People 2000,'' 
see the section Where to Obtain Additional Information.)

[[Page 32341]]

Authority

    This program is authorized under Sections 301 and 317(k)(2), of the 
Public Health Service Act (42 U.S.C. 241 and 247b(k)(2) as amended.

Smoke-Free Workplace

    CDC strongly encourages all recipients to provide a smoke-free 
workplace and to promote the nonuse of all tobacco products, and Public 
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
facilities that receive Federal funds in which education, library, day 
care, health care, and early childhood development services are 
provided to children.

Eligible Applicants

    Applications may be submitted by public and private, nonprofit and 
for-profit organizations, and governments and their agencies. Thus, 
universities, colleges, research institutes, community-based 
organizations, hospitals, other public and private organizations, State 
and local health departments or their bona fide agents or 
instrumentalities, federally recognized Indian tribal governments, 
Indian tribes or Indian tribal organizations, and small, racial-ethnic 
or women-owned businesses are eligible to apply.

Availability of Funds

    Approximately $1,200,000 is available in FY 1997 to fund four 
awards. It is expected that the average award will range from $275,000 
to $325,000. The awards are expected to begin on or about September 30, 
1997, and will be made for a 12-month budget period within a project 
period of up to five years. Continuation awards will be made on the 
basis of satisfactory progress and the availability of funds. Funding 
estimates may vary and are subject to change. Applications requesting 
greater than $325,000 will not be considered for funding.

Use of Funds

Restrictions on Lobbying

    Applicants should be aware of restrictions on the use of HHS funds 
for lobbying of Federal or State legislative bodies. Under the 
provisions of 31 U.S.C. Section 1352 (which has been in effect since 
December 23, 1989), recipients (and their subtier contractors) are 
prohibited from using appropriated Federal funds (other than profits 
from a Federal contract) for lobbying Congress or any Federal agency in 
connection with the award of a particular contract, grant, cooperative 
agreement, or loan. This includes grants/cooperative agreements that, 
in whole or in part, involve conferences for which Federal funds cannot 
be used directly or indirectly to encourage participants to lobby or to 
instruct participants on how to lobby.
    In addition, the FY 1997 HHS Appropriations Act, which became 
effective October 1, 1996, expressly prohibits the use of 1997 
appropriated funds for indirect or ``grass roots'' lobbying efforts 
that are designed to support or defeat legislation pending before State 
legislatures. This new law, Section 503 of Pub. L. No. 104-208, 
provides as follows:

    Sec. 503(a) No part of any appropriation contained in this Act 
shall be used, other than for normal and recognized executive-
legislative relationships, for publicity or propaganda purposes, for 
the preparation, distribution, or use of any kit, pamphlet, booklet, 
publication, radio, television, or video presentation designed to 
support or defeat legislation pending before the Congress, * * * 
except in presentation to the Congress or any State legislative body 
itself.
    (b) No part of any appropriation contained in this Act shall be 
used to pay the salary or expenses of any grant or contract 
recipient, or agent acting for such recipient, related to any 
activity designed to influence legislation or appropriations pending 
before the Congress or any State legislature.

    Department of Labor, Health and Human Services, and Education, and 
Related Agencies Appropriations Act, 1997, as enacted by the Omnibus 
Consolidated Appropriations Act, 1997, Division A, Title I, Section 
101(e), Pub. L. No. 104-208 (September 30, 1996).

Background: HIV/AIDS in the U.S. Prison Population

    There are over 6 million adults or 2.6% of the total adult U.S. 
population under some form of correctional custody on any given day. A 
recent national survey of routine STD testing in correctional 
facilities found positivity rates for syphilis among inmates that range 
from 0% to 17% and positivity rates for gonorrhea ranging from 0% to 
32.5%. The prevalence of AIDS among inmates is 5.2 per thousand, or 
nearly six times the total U.S. adult population rate of 0.9 per 
thousand. HIV seroprevalence rates among prison populations vary by 
region, ranging from 2% to as high as 26%. Approximately 93% of all 
inmate deaths from AIDS are among men. Compared to men in the general 
population, men entering prisons typically have substantially higher 
rates of STDs, HIV infection and risk behaviors for HIV infection such 
as injecting drug use, sexual contact with injecting drug using 
partners, homemade tattoos and other blood exposures.
    In the United States, injection drug users represent about 25% of 
all AIDS cases and 42% of cases acquired through heterosexual 
transmission have been attributed to sexual contact with an injection 
drug user. In 1991 there were over 177,750 injection drug users in 
State prisons alone. Nationwide, approximately 70% of inmates have a 
history of injection drug use. It is obvious that prisons are important 
settings for reaching men who are at increased risk for HIV infection 
with risk reduction information.
    Unfortunately, a recent survey of prison administrators found that 
from 1992 to 1994, the number of prisons that provided instructor-led 
HIV educational programs for inmates declined. In addition, the number 
of prison systems that made HIV education available to inmates through 
videos and other audiovisual materials also declined. In spite of the 
tremendous increase in the numbers of young men who are incarcerated, 
very few prevention programs have been specifically designed and 
evaluated for young men in prison.
    Prison populations provide a means of accessing large numbers of 
young men who have engaged in high risk behaviors and are likely to do 
so again upon their release from prison. Without support and assistance 
in making the transition from prison life to a stable life back in 
their communities, it is probable that inmates may relapse to drug use 
and risky sexual behaviors. Young male inmates may be more readily 
encouraged to alter their risky behaviors compared to older inmates who 
are more likely to have longer histories of risky behavior and because 
of longer sentences, will have less opportunity to practice risk 
reduction behaviors. According to national figures most inmates remain 
incarcerated for an average of 18 months. An intervention that begins 
to address HIV and STD prevention immediately prior to young men's 
release from prison and that continues to provide ongoing intervention 
and support for behavior change following release is a much needed 
model. Therefore, it is vital that an HIV and STD prevention 
intervention for this population be designed, tested and evaluated in 
order to assist communities in addressing the unmet risk-reduction 
needs of this population.

Purpose

    The objective of this announcement is to advance the field of HIV-
prevention science so that local communities will have available to 
them a range of scientifically sound intervention

[[Page 32342]]

strategies to use in their prevention programs for young men (ages 18 
to 25) in prisons. To reach this goal it is essential that programs 
work with communities to accomplish this research so that interventions 
will be feasible and acceptable to the community. A critical goal of 
this research is to connect local researchers with community and 
prison-based prevention programs in order to build the capacity of 
local communities to sustain intervention work after the research is 
completed.
    Behavioral intervention research of this type often involves three 
distinct phases. The first phase involves the collection of qualitative 
and quantitative data that leads to a better understanding of the study 
population, its risk-related practices, as well as barriers and 
facilitators to the adoption and maintenance of reduced behavioral risk 
practices. In the second phase, this information is used to develop an 
intervention strategy, which is then piloted on a small scale to 
determine the feasibility and acceptability of the intervention. In the 
third phase, a refined intervention model is tested to evaluate its 
ability to influence risk-related practices and attitudes. This 
announcement is designed to support local research efforts in each of 
these three phases.
    Facilitating participation in the development of a common cross-
site research protocol is an essential objective of this announcement. 
The collection of comparable data across sites provides a number of 
significant advantages with regard to advancing the field of 
intervention research. First, the prevalence of risk-related practices 
and beliefs can be systematically evaluated across different 
populations and regions of the country. Second, collection of 
comparable process and outcome evaluation data allows the relative 
effectiveness of different intervention strategies to be assessed. 
Third, the inability of a single-site project to recruit sufficient 
participants to reliably measure biological outcome measures such as 
STD and HIV incidence can be overcome with a multi-site effort.

Program Requirements

    To achieve the purpose of this project, the recipient will be 
responsible for the activities under A. (Recipient Activities). The CDC 
will provide assistance with the activities listed under B. (CDC 
Activities).

A. Recipient Activities

    To achieve the objectives of this announcement, it is recommended 
that each cooperative agreement recipient form a multi-disciplinary 
research team, led by behavioral and social scientists skilled in 
conducting intervention research. This team will guide the 
implementation of research and intervention protocols that will be 
developed collaboratively by the cooperative agreement recipients. To 
ensure the feasibility and acceptability of the intervention strategy 
in the local community, the research team should develop formal 
mechanisms to solicit on-going input from relevant stakeholders such as 
inmate representatives, corrections staff, staff from participating 
community based organizations, and data analysts.
    The multi-disciplinary research team will:
    1. Collaborate with other cooperative agreement recipients in 
developing a common research protocol.
    2. Following the common study protocol, conduct formative research 
to describe the risk behaviors of the study population as well as 
psychosocial and other factors that influence their HIV and STD risk 
behavior.
    3. Following the common study protocol, pilot test and rigorously 
evaluate the impact of the intervention developed earlier in the 
project.
    4. Collaborate with other cooperative agreement recipients in data 
analysis and dissemination of research findings so that they are 
accessible and usable to local communities and other researchers.
    Given the collaborative nature of this effort, it is anticipated 
that key staff from each cooperative agreement recipient's agency will 
attend four meetings of all the cooperative agreement recipients each 
year and participate in regular telephone conference calls throughout 
the duration of the project.

B. CDC Activities

    CDC staff will collaborate with cooperative agreement recipients, 
providing guidance and coordination throughout the duration of the 
project. Activities that will be conducted by the CDC include:
    1. Participate in developing research protocols including data 
collection procedures and instruments;
    2. Assist in the scientific and operational conduct of the research 
project to ensure that HIV prevention science and community needs are 
met;
    3. Coordinate cross-site data aggregation and analyses to ensure 
that HIV prevention science and community needs are met.
    4. Participate in the preparation of study results for publication.
    It is anticipated that within the first 3 months of the cooperative 
agreement, all recipients will complete the common research protocol 
and in the next 3 months pilot test its components. Around the 18th 
month of the project, recipients will agree on the essential components 
of the common intervention protocol for pilot testing. Following the 
pilot testing, the feasibility of implementing a rigorous research 
evaluation of the intervention will be assessed. Intervention studies 
that are scientifically rigorous, acceptable to the study population, 
and likely to lead to reductions in HIV and STD risk will move ahead to 
the intervention trial phase.

Technical Reporting Requirements

    An original and two copies of semiannual progress reports are 
required. Time lines for the quarterly reports will be established at 
the time of award. Final financial status and performance reports are 
required no later than 90 days after the end of the project period. All 
reports are to be submitted to the Grants Management Branch, 
Procurement and Grants Office, CDC.

Application Content

    Applications must be developed in accordance with PHS Form 398 (OMB 
Number 0925-0001), information contained in the program announcement 
and the instructions provided below. Applicants are required to submit 
an original and two copies of the application. All page limits 
specified in the PHS 398 application kit must be adhered to with the 
exception that sections a-d of the Research Plan must not exceed 15 
pages in length. Material in appendices should be one-sided only.
    The following information should be addressed within the Research 
Plan section of the application narrative:

1. Population and Facility

    a. Demonstrate familiarity with HIV/STD issues faced by young men 
making the transition back to their communities and identify the 
factors associated with the transmission of HIV/STD within the proposed 
study population;
    b. Describe the prison facility and the characteristics of the 
participants who will be recruited, including the total number of 
incarcerated young men aged 18-25. Describe with regard to men ages 18 
to 25: overall number of inmates released from prison each month for 
the past year, number of men on parole, number of violent and non-
violent inmates, rates of recidivism, race/ethnicity data, number of 
men tested for

[[Page 32343]]

HIV, the percentage of young men who are HIV positive, the percentage 
of new inmates who test positive for an STD and the percentage that are 
diagnosed with an STD during the period of incarceration;
    c. Describe the plans to involve young men, correctional staff, and 
service providers in the development of research and intervention 
activities;
    d. Include procedures for obtaining informed consent, Institutional 
Review Board (IRB) clearance, and maintaining participant 
confidentiality;
    e. Describe ongoing HIV/STD education and prevention activities 
with this population within the prison facility and in the community;
    f. Describe linkages between the prison facility, local community 
health department resources, and community based organizations. Include 
a list with descriptions of referral organizations and their services. 
Also enclose letters of support from each organization that are 
specific in identifying the services that they will provide;
    g. Include a letter of support from the Warden and the Medical 
Director of the participating correctional facilities that states they 
will participate in the project and support the research and 
intervention activities.

2. Formative Research Plan

    a. Describe the plan to conduct formative research. Discuss what 
factors will be examined and the rationale for studying these factors 
based on the scientific literature;
    b. Provide a statement of the willingness of the research team to 
work collaboratively with the other cooperative agreement recipients in 
developing a common research protocol and to disseminate study 
findings;
    c. Describe plans for following participants for a minimum of six 
months following their release from prison; and,
    d. Describe the methods for collecting and analyzing qualitative 
and quantitative data.

3. Research and Intervention Capability of Applicant

    a. Describe the professional training and relevant experience of 
the research team;
    b. Provide descriptions and major findings of HIV-related research 
and behavioral intervention studies that have been conducted by members 
of the research team;
    c. Include a table of current and previous relevant research 
projects, their principal investigators, status, sources and levels of 
funding; and
    d. Include in the appendix, the curriculum vitae for key staff 
members as well as memoranda of agreement that document activities to 
be performed by any external experts, consultants, or collaborating 
agencies under the cooperative agreement.

4. Staffing, Facilities, and Time Line

    a. Explain the proposed staffing structure (positions/titles), the 
percentage of time each staff member commits to this study and other 
projects, and the division of duties and responsibilities for the 
project;
    b. Identify and describe the key roles of behavioral scientists and 
other staff essential to the conduct and the completion of the project;
    c. Describe the duties and responsibilities of project personnel to 
conduct project oversight and data management;
    d. Describe the existing facilities, equipment, computer software, 
data processing capacity, and describe the procedures to ensure the 
security of research data; and,
    e. Provide a time line for the completion of the proposed research.

5. Budget

    Provide a detailed, line-item budget for the project and a budget 
narrative that justifies each line-item.

Evaluation Criteria

    Applications that meet the eligibility requirements will be 
reviewed and evaluated according to the following criteria:

1. Familiarity With HIV/AIDS and STD Risk Behaviors of Young Men. (20 
Points)

    a. Extent of applicant's knowledge of HIV/STD issues faced by young 
men ready for release to their communities and familiarity with the 
relevant research;
    b. Thoroughness of the description of risk behaviors that are 
associated with the transmission of HIV/STD in the proposed study 
population;
    c. Inclusion of a description of the facility and the ability to 
show the availability of sufficient numbers of participants to achieve 
the study objectives, including the total number of incarcerated young 
men aged 18-25, described in terms of the following: overall number of 
inmates released each month for the past year, number of men on parole, 
number of violent and non-violent inmates, rates of recidivism, race/
ethnicity data, number of men tested for HIV, the percentage that are 
positive in the institution annually, the percentage of new inmates who 
test positive for an STD and the percentage that are diagnosed with an 
STD during the period of incarceration;
    d. Quality of the plan to involve young men, correctional staff, 
and service providers in the development of research and intervention 
activities;
    e. Adequacy of the procedures for obtaining informed consent, IRB 
clearance and maintaining participant confidentiality;
    f. Documentation and coordination of any ongoing HIV/STD education 
and prevention activities with this population within the prison 
facility and in the community;
    g. Adequacy of the linkages with local community health department 
resources, and community based organizations. Presence of list of 
referral organizations and their services. Presence of letters of 
support from each organization specifying the service that they will 
provide; and,
    h. Inclusion of the letter of support from the Warden and the 
Medical Director of the selected correctional facility stating their 
willingness to participate in the project and to actively support the 
research and intervention activities.

2. Formative Research Plan (30 Points)

    a. Thoroughness of the applicant's understanding of the scientific 
literature related to HIV/STD risk and risk reduction with the target 
population;
    b. Quality of the plan to conduct formative research that will 
yield information relevant to the development of HIV/STD risk reduction 
interventions for young men who are ready for release;
    c. Presence of a statement showing the willingness of the research 
team to work collaboratively with the CDC and the other cooperative 
agreement recipients in developing a common research protocol and to 
disseminate study findings;
    d. The proposed plan for the inclusion of racial and ethnic 
minority populations for appropriate representation and the proposed 
justification when representation is limited or absent;
    e. Adequacy of plans to test the feasibility of following 
participants for six months following their release from prison; and,
    f. Quality of the methods described for collecting and analyzing 
qualitative and quantitative data.

3. Research and Intervention Capability (35 Points)

    a. Quality of the professional training and relevant research 
experience of the research team;
    b. Relevance and quality of HIV-related research and behavioral

[[Page 32344]]

intervention studies that have been conducted by members of the 
research team;
    c. Inclusion of a table of current and previous relevant research 
projects, their principal investigators, status, sources and levels of 
funding; and,
    d. Completeness of requested materials in the appendix, the 
curriculum vitae for key staff members as well as memoranda of 
agreement that clearly and specifically document activities to be 
performed by any external experts, consultants, or collaborating 
agencies under the cooperative agreement.

4. Staffing, Facilities, and Time Line (15 Points)

    a. Adequacy of the proposed staffing structure (positions/titles), 
the percentage of time each staff member commits to this and other 
projects, and the division of duties and responsibilities for the 
project;
    b. Clarity and appropriateness of the key roles of behavioral 
scientists and other staff essential to the conduct and the completion 
of the project;
    c. Clarity of the described duties and responsibilities of project 
personnel to conduct project oversight and data management;
    d. Adequacy of the existing facilities, equipment, computer 
software, data processing capacity, and the procedures to ensure the 
security of research data; and,
    e. Completeness and reasonableness of time line for the proposed 
research.

5. Budget (Not Scored)

    Extent to which the budget is reasonable, itemized, clearly 
justified, and consistent with the intended use of the funds.

Executive Order 12372 Review

    Applications are subject to Intergovernmental Review of Federal 
Programs as governed by Executive Order (E.O.) 12372. E.O. 12372 sets 
up a system for State and local government review of proposed Federal 
assistance applications. Applicants (other than federally recognized 
Indian tribal governments) should contact their State Single Point of 
Contact (SPOC) as early as possible to alert them to the prospective 
applications and receive any necessary instructions on the State 
process. For proposed projects serving more than one State, the 
applicant is advised to contact the SPOC for each affected State. A 
current list of SPOCs is included in the application kit. If SPOCs have 
any State process recommendations on applications submitted to CDC, 
they should send them to Van Malone, Grants Management Officer, Grants 
Management Branch, Procurement and Grants Office, Centers for Disease 
Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, 
Mailstop E15, Atlanta, GA 30305, no later than 30 days after the 
application deadline. The granting agency does not guarantee to 
``accommodate or explain'' for State process recommendations it 
receives after that date.
    Indian tribes are strongly encouraged to request tribal government 
review of the proposed application. If tribal governments have any 
tribal process recommendations on applications submitted to the CDC, 
they should forward them to Van Malone, Grants Management Officer, 
Grants Management Branch, Procurement and Grants Office, Centers for 
Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., 
Room 300, Mailstop E15, Atlanta, GA 30305. This should be done no later 
than 30 days after the application deadline date. The granting agency 
does not guarantee to ``accommodate or explain'' for tribal process 
recommendations it receives after that date.

Public Health System Reporting Requirements

    This program is subject to the Public Health System Reporting 
Requirements. Under these requirements, all community-based 
nongovernmental applicants must prepare and submit the items identified 
below to the head of the appropriate State and/or local health 
department agency(s) in the program area(s) that may be impacted by the 
proposed project no later than the receipt date of the Federal 
application. The appropriate State and/or local health agency is 
determined by the applicant. The following information must be 
provided:
    A. A copy of the face page of the application (SF 424).
    B. A summary of the project that should be titled ``Public Health 
System Impact Statement'' (PHSIS), not exceed one page, and include the 
following:
    1. A description of the population to be served
    2. A summary of the services to be provided; and,
    3. A description of the coordination plans with the appropriate 
State and/or local health agencies.
    If the State and/or local health official should desire a copy of 
the entire application, it may be obtained from the State Single Point 
of Contact (SPOC) or directly from the applicant.

Catalog of Federal Domestic Assistance Number

    The Catalog of Federal Domestic Assistance number is 93.941.

Other Requirements

Paperwork Reduction Act

    Projects that involve the collection of information from 10 or more 
individuals and funded by the cooperative agreement will be subject to 
review by the Office of Management and Budget (OMB) under the Paperwork 
Reduction Act.

Human Subjects

    If the proposed project involves research on human subjects, the 
applicant must comply with the Department of Health and Human Services 
Regulations, 45 CFR Part 46, regarding the protection of human 
subjects. Assurance must be provided to demonstrate that the project 
will be subject to initial and continuing review by an appropriate 
institutional review committees. In addition to other applicable 
committees, Indian Health Service (IHS) institutional review committees 
also must review the project if any component of IHS will be involved 
or will support the research. If any American Indian community is 
involved, its tribal government must also approve that portion of the 
project applicable to it. The applicant will be responsible for 
providing assurance in accordance with the appropriate guidelines and 
form provided in the application kit.

Racial and Ethnic Minorities

    It is the policy of the Centers for Disease Control and Prevention 
(CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) 
to ensure that individuals of the various racial and ethnic groups will 
be included in CDC/ATSDR-supported research projects involving human 
subjects, whenever feasible and appropriate. Racial and ethnic groups 
are those defined in OMB Directive No. 15 and include American Indian, 
Alaskan Native, Asian, Pacific Islander, Black and Hispanic. Applicants 
shall ensure that racial and ethnic minority populations are 
appropriately represented in applications for research involving human 
subjects. Where clear and compelling rationale exist that inclusion is 
inappropriate or not feasible, this situation must be explained as part 
of the application. This policy does not apply to research studies when 
the investigator cannot control the race, ethnicity and/or sex of 
subjects. Further guidance to this policy

[[Page 32345]]

is contained in the Federal Register, Vol. 60, No. 179, pages 47947-
47951, and dated September 15, 1995.

HIV/AIDS Requirements

    Recipients must comply with the document entitled Content of AIDS-
Related Written Materials, Pictorials, Audiovisuals, Questionnaires, 
Survey Instruments, and Educational Sessions (June 1992), a copy of 
which is included in the application kit. At least one member of the 
program review panel must be an employee (or designated representative) 
of the health department consistent with the Content guidelines. The 
names of the review panel members must be listed on the Assurance of 
Compliance for CDC 0.1113, which is also included in the application 
kit. The recipient must submit, an attachment to the quarterly 
summaries, the program review panel's report that all material have 
been reviewed and approved.

Application Submission and Deadlines

1. Preapplication Letter of Intent

    A non-binding letter of intent-to-apply is required from potential 
applicants. An original and two copies of the letter should be 
submitted to the Grants Management Branch, CDC (see ``Applications'' 
for the address). It should be postmarked no later than July 14, 1997. 
The letter should identify the announcement number, name of principal 
investigator, and specify the activity(ies) to be addressed by the 
proposed project. The letter of intent does not influence review or 
funding decisions, but it will enable CDC to plan the review more 
efficiently, and will ensure that each applicant receives timely and 
relevant information prior to application submission.

2. Applications

    An original and two copies of the application PHS Form 398 (OMB 
Number 0925-0001) must be submitted to Van Malone, Grants Management 
Officer, Grants Management Branch, Procurement and Grants Office, 
Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry 
Road, NE., Room 300, Mailstop E-15, Atlanta, GA 30305, on or before 
August 7, 1997.

3. Deadlines

    a. Applications shall be considered as meeting the deadline if they 
are either:
    (1) Received on or before the deadline date; or,
    (2) Sent on or before the deadline date and received in time for 
submission to the objective review group. (Applicants must request a 
legibly dated U.S. Postal Service postmark or obtain a legibly dated 
receipt from a commercial carrier or the U.S. Postal Service. Private 
metered postmarks shall not be acceptable as proof of timely mailing.)
    b. Applications that do not meet the criteria in 3.a.(1) or 3.a.(2) 
above are considered late applications. Late applications will not be 
considered in the current competition and will be returned to the 
applicant.

Where To Obtain Additional Information

    A complete program description, information on application 
procedures, an application package and business management technical 
assistance may be obtained from Van Malone, Grants Management Officer, 
Grants Management Branch, Procurement and Grants Office, Centers for 
Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., 
Room 300, Mailstop E-15, Atlanta, GA 30305, telephone (404) 842-6575, 
email: [email protected].
    Programmatic technical assistance may be obtained from Robert 
Kohmescher, Division of HIV/AIDS Prevention, National Center for HIV/
STD/TB Prevention, Centers for Disease Control and Prevention (CDC), 
1600 Clifton Road, NE., Mailstop E-44, Atlanta, GA 30333, telephone 
(404) 639-8302, email: [email protected].
    Please refer to Announcement 750 when requesting information and 
submitting an application. Potential applicants may obtain a copy of 
``Healthy People 2000,'' (Full Report, Stock No. 017-001-00474-0) or 
``Healthy People 2000,'' (Summary Report, Stock No. 017-001-00473-1) 
referenced in the Introduction, through the Superintendent of 
Documents, Government Printing Office, Washington, DC 20402-9325, 
telephone (202) 512-1800.

Internet Home Page

    The announcement will be available on one of two Internet sites on 
the publication date: CDC's home page at http://www.cdc.gov, or at the 
Government Printing Office home page (including free access to the 
Federal Register) at http://www.access.gpo.gov.

    Dated: June 9, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 97-15510 Filed 6-12-97; 8:45 am]
BILLING CODE 4163-18-P